1 February 2012
Australian biopharmaceutical company Immuron Limited (ASX: IMC), manufacturer of Travelan®, has entered into a collaboration agreement with Monash University to develop a product or products that will be aimed at both prevention and treatment of Clostridium difficile (C. difficile) infections.
The therapeutic will be based on Immuron’s hyper-immune colostrum platform technology, with its proven safety.
C. difficile infections have become a major medical problem especially in hospitals and long-term care facilities because the bacteria produce toxins that cause inflammation of the colon, causing severe diarrhoea and, in serious cases, death. An estimated 28,000 people die each year from these infections in the USA alone.
Monash University has received government funding through an ARC Linkage grant. As is typical with these grants, Immuron and Monash will together own the technology to be generated and Immuron has the exclusive global commercialisation rights.
C. difficile infections result in an estimated annual economic burden of more than US$10 billion globally. Current therapies are based on antibiotics that are not fully effective and that encourage the emergence of antibiotic-resistant strains. However, Immuron’s hyper-immune colostrum platform technology has the potential to offer a new-paradigm effective therapeutic.